GC Biopharma

At a glance

GC Biopharma filed 50 disclosures in the last 12 months, including 3 earnings, 3 insider, 2 5% holder and 1 m&a. The most recent key filing was on Aug 7.

Revenue for 2025 was ₩1.99T, up 18.5% on 2024. Operating margin was 3.5% against 1.9% a year earlier. Debt was 113% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩857B and operating profit of ₩13.5B.

The 2025 annual report lists 2,351 employees with an average tenure of 9.9 years and average pay of ₩73.1M, #518 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩312M each on average. It paid ₩1,500 per common share in cash dividends, against ₩1,500 a year earlier (+0%). ㈜녹십자홀딩스 and related parties held 51.41% at year end.

From the 2025 annual report

Staff: 2,351 (1,707 men, 644 women), of whom 228 on fixed-term contracts. Total pay for the year: ₩172B. Directors and auditors: 7, paid ₩2.2B in total.

Dividends (common shares)

Largest shareholder

㈜녹십자홀딩스 holds 50.06%; with 13 related parties the group holds 51.41% of common shares at year end (from 51.42% at the start of the year).

Individuals paid ₩500M or more

Auditor: 한영회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary